Seattle biotech startup BrainChild Bio has raised $116 million to advance an experimental CAR T cell therapy for one of the deadliest forms of childhood brain cancer.

The Series A financing will primarily fund a pivotal Phase 2 clinical trial of an investigational therapy being developed for diffuse intrinsic pontine glioma, or DIPG. The rare brainstem tumor primarily affects children ages 5 to 10 and has few treatment options.

The financing was led by an undisclosed private family fund and foundation, with participation from BrainChild Bio’s initial investor, Seattle Children’s, and new investor WRF Capital.

BrainChild Bio is building on CAR T cell technology developed at Seattle Children’s and licensed exclusively to the company in 2023. The approach involves genetically engineering a patient’s own T cells to recognize and attack cancer cells.

The company says its new therapy has now entered its ILLUMINATE Phase 2 study, designed as a registration-stage trial that could eventually support an application to the U.S. Food and Drug Administration.

DIPG presents a particularly difficult challenge for cancer researchers because the tumors grow in the brainstem, an area critical to basic functions, and the blood-brain barrier can limit the ability of treatments to reach the tumor.

BrainChild Bio’s approach delivers the CAR T cells directly into cerebrospinal fluid through an implanted catheter, allowing the cells to reach the tumor locally and potentially be administered repeatedly.

About 300 children in the U.S. are diagnosed with DIPG each year, a devastating brain tumor with no cure and few treatment options. Radiation is the current standard of care, but children diagnosed with DIPG have a median overall survival of only about 11 months.

BrainChild Bio also plans to use proceeds from the new financing to advance a CAR T therapy designed to target three different cancer markers, toward initial clinical testing in glioblastoma.

The company was founded by Michael Jensen, who previously helped develop the underlying work at Seattle Children’s and was a co-founder of Umoja Biopharma and Juno Therapeutics. The CEO is Steven Brugger, who most recently served as founder and CEO of Affinivax, a biotech company which was acquired by GSK for $3.3 billion in 2022. 

“This financing enables us to chart our path forward to serve the children and families afflicted with devastating brain tumors and represents a new paradigm for treating CNS brain tumors in children and adults,” Jensen said in a statement. “Our team at BrainChild Bio is steadfast in its commitment to harness CAR T cell technology in CNS tumors and we are uniquely positioned to do so.”

"Billionaire Bill Ackman's life was upended this February when his 26-year-old daughter collapsed in her Brooklyn apartment, suffering a brain hemorrhage that would render her unable to move, speak or see," writes the Washingon Post. But then... The hedge fund manager did what any good father would do — at least, any father with vast financial resources and what friends describe as a "Mr. Fix-It" tendency. He sprung into action, getting her topline care at New York City's Mt. Sinai Hospital and consulting a network of well-connected friends all over the world. He helped her access a novel cell therapy that has been gaining traction among longevity enthusiasts, who are seeking ways to prolong human life. And then — motivated by a newfound desire to accelerate scientific research — he vowed to spend more than $400 million to launch an institute dedicated to longevity and brain health... He posted this week that the U.S. Food and Drug Administration, in May, gave his daughter Lucy's medical team a first-time emergency authorization to transplant mitochondria — the energy-producing part of human cells — from her leg muscle to her eyes, in the hopes that the tiny cell powerhouses would facilitate healing in her optic nerves and perhaps even restore her vision. Ackman's story highlights the increasingly prominent role of the ultra-wealthy in making expensive medical bets on longevity treatments and other novel therapies, altering the direction of research as federal funding for science declines in the second Trump administration. But his saga is a deeply personal one, spurred by his daughter's medical crisis. The focus on longevity by Ackman, who made billions on Wall Street as a hedge fund manager, is aligned with similarly ambitious efforts from some of Silicon Valley's biggest names. OpenAI CEO Sam Altman has backed Retro Biosciences, a start-up whose goal is to add 10 healthy years to the human lifespan through cellular reprogramming. Amazon founder Jeff Bezos is reportedly a funder of Altos Labs, which focuses on cellular rejuvenation and resilience... Billionaire investor Peter Thiel, Google co-founder Sergey Brin and Oracle co-founder Larry Ellison are also deeply invested in life-extension methods and attempts to rewrite the biology of aging... The therapy given to Ackman's daughter Lucy, known as mitochondrial transplantation, is of great interest not only to people who have suffered injuries, but to longevity-focused scientists who believe that mitochondria may hold promise for reversing some of the effects of aging... In recent years, scientists have discovered that mitochondria have many other functions beyond converting food into energy. They serve as clearinghouses for damaged cells, opening up the possibility that they can help with cell regeneration and healing, said Daria Mochly-Rosen, professor of chemical and systems biology at the Stanford University School of Medicine and co-author of " The Life Machines: How Taking Care of Your Mitochondria Can Transform Your Health." "I am one of those who believes that focusing on mitochondrial health is a way to address many human diseases, including aging itself," she said. "It's exciting."

Read more of this story at Slashdot.

A Kirkland, Wash.-based biotech company led by former Athira Pharma CEO Leen Kawas has raised $35 million in a Series A round led by Propel Bio Partners, the Los Angeles investment firm where Kawas is a co-founder and managing general partner.

EIT Pharma said Monday that the oversubscribed round also drew participation from Good Ventures, Arrowtown and others. The company said the money will support FDA review of lonafarnib, an oral treatment candidate for chronic hepatitis D, along with manufacturing and commercial preparations, subject to regulatory approval.

The Food and Drug Administration accepted the company’s New Drug Application for review on Aug. 11.

Lonafarnib came to EIT Pharma through the 2024 bankruptcy of Eiger BioPharmaceuticals, in a court-supervised sale that closed that September. The same sale included peginterferon lambda, which EIT Pharma is developing for severe respiratory infections.

Kawas, EIT Pharma’s CEO, said in a news release Monday that the oversubscribed round validates the company’s founding belief that “advancing important medicines is about recognizing unrealized potential.”

Chronic hepatitis D is a serious liver disease that affects people who are already infected with hepatitis B. The FDA approved the first U.S. treatment for chronic hepatitis D in May: Gilead’s injectable Hepcludex, or bulevirtide-gmod. EIT Pharma is positioning lonafarnib as a potential oral alternative, if approved.

Kawas resigned as CEO of Athira Pharma in 2021 after a board investigation found she had altered images in research she co-authored as a graduate student. She said at the time that the changes were enhancements that did not alter the underlying data.

Athira has since changed its name to LeonaBio and shifted its focus from Alzheimer’s disease to breast cancer.

Arzeda designs enzymes for products ranging from laundry detergent to stevia. But when it comes time to manufacture at commercial scale, the Seattle-based startup often has to look overseas.

That’s why, when a federal biotechnology commission visited Seattle on Tuesday, the industry came forward with a problem: They have the science, but lack the infrastructure and workforce pipeline to keep innovation on U.S. soil.

Arzeda’s designs reach an estimated 1.8 billion consumers worldwide, and the company has spent the better part of two decades building its technology. The company’s enzymes, sometimes designed in days rather than weeks thanks to AI, are largely manufactured in Western Europe and India — with one U.S. contract manufacturing partner in Wisconsin. 

Finding domestic manufacturers with the expertise and capacity to make these specialized proteins has been difficult, CEO Alexandre Zanghellini said. And for a company trying to commercialize new biotechnology, he added, manufacturing delays can be “catastrophic.” 

The federal group visiting Seattle — the National Security Commission on Emerging Biotechnology — was created by Congress to address these kinds of problems. Since 2022, the team of 11 bipartisan experts have examined how biotech intersects with national security, and what the U.S. needs to do to remain competitive with China. 

Last year, the commission drafted a report to Congress with 49 recommendations spanning at least $15 billion in federal investment over five years, with policies to get more private capital into biotechnology, build domestic manufacturing capacity, strengthen the workforce and reduce vulnerabilities in the supply chain. 

Now, with the commission sunsetting in December, its members are taking their case around the country. 

The science is here, the infrastructure isn’t

In Seattle, the urgent matter is finding a way to keep biotechnology breakthroughs in the United States. Alexander Titus, a commission member who has headed AI-focused biotech initiatives in Seattle and nationwide, said Washington stands out for its early innovation and research. 

“Companies like Arzeda are having pretty serious leadership roles in the AI and bio space,” he told GeekWire. “A lot of the work we have done in the commission has revolved around helping the U.S. meet the moment when it comes to this nexus.” 

Institutions like the University of Washington, Fred Hutchinson Cancer Center and the Allen Institute have helped build a deep life-sciences ecosystem in Washington. UW’s Institute for Protein Design, led by 2024 Nobel Prize winner David Baker, has spun out more than 20 companies.

One is Arzeda, which has an increasingly fast agentic workflow that can fine-tune a model, suggest the next experiment, and allow researchers to test thousands of sequences in a single round. The company’s first AI-designed commercial product was a stevia ingredient launched in 2024; it’s now negotiating a $44 million contract with the federal Defense Threat Reduction Agency related to biothreat response. 

While technology is moving quickly, the infrastructure needed to commercialize it is not — creating what Seattle biotech leaders called a “valley of death” between research and manufacturing.

The U.S. has federal funding for basic research, as well as a venture-capital system that can finance early-stage discoveries. But once a company needs to build or access physical infrastructure for commercial-scale manufacturing, the financing becomes much harder. Venture capital investors don’t see the returns attractive enough, Zanghellini said. Banks aren’t eager to finance them, either. 

The pull of overseas manufacturing

Meanwhile, China has spent two decades making biotechnology a strategic priority, and its 2026 Five-Year Plan doubles down on areas including biomedicine, biomanufacturing, pharmaceuticals and brain-computer interfaces. For U.S. companies in the race, that can create an uncomfortable incentive: If the infrastructure is cheaper and faster somewhere else, that’s where the work often goes. 

Last year, Seattle-based Sana Biotechnology canceled plans for a manufacturing plant that was supposed to employ hundreds of workers in Bothell, Wash., instead opting for a contract manufacturer elsewhere to cut costs. Snehal Patel, the company’s executive vice president and chief technical officer, said on Tuesday he’s optimistic the Seattle area could compete on speed and cost with China’s fully integrated supply chain — with the right resources.

Ideally, manufacturing facilities in the U.S. would offer flexibility and knowledge in different products and processes, while ensuring trade secret protection.

The commissioners recognize this need; among their recommendations for Congress is a nationwide manufacturing network for precommercial, bioindustrial product scale-up. That could address the problem Seattle companies face: a startup shouldn’t have to choose between sending manufacturing overseas or trying to build an entire facility itself.

The commission has also recommended requiring companies to disclose points of supply-chain vulnerability in foreign countries of concern. If a geopolitical conflict disrupts the supply of medicines or other biological products, Titus said, the consequences can reach Americans far from any battlefield.

“Being able to keep and maintain our leadership in certain industries allows us to have the edge in any given situation,” he said. “We want our industries to be able to produce here…it’s truly national security in the broadest sense at this point.”

Building the workforce pipeline

To accomplish this, companies need a stronger industrial biomanufacturing workforce.

Rebecca Bryant, Fred Hutch’s director of government relations and a former staffer for Rep. Adam Smith, said while Washington trains well for research, there’s no equivalent pipeline into entry-level biomanufacturing jobs. Titus sees the issue as part of a broader problem of “bioliteracy” — that biology should be a basic problem-solving tool in the same way that engineering, chemistry and computing are, rather than a specialized field understood by few. 

In Washington, the Hutch Advance partnership with Shoreline Community College trains and places lab technicians, while Sana Biotechnology has worked on a model for moving workers into biomanufacturing. Seattle industry leaders suggested a state or federally-supported workforce consortium to bolster the effort. Meanwhile, the commission has urged Congress for more biomanufacturing training support. 

According to the commission, the next three years will determine whether the U.S. remains the global leader in biotechnology or cedes the future to China. Of the commission’s 49 recommendations, Titus said, 26 have been written into law in some capacity. The next step is in the hands of Congress, federal agencies, states and the industry itself. 

A federal judge has entered a final judgment requiring Guardant Health to pay more than $245 million to Seattle biotech TwinStrand Biosciences and the University of Washington over DNA sequencing technology developed at the university.

The judgment, entered Friday in U.S. District Court in Delaware, follows a 2023 jury verdict that found Guardant willfully infringed two patents covering TwinStrand’s Duplex Sequencing technology.

The case also establishes a continuing revenue stream for the university and TwinStrand from some of Guardant’s products.

The court’s final judgment includes $83.4 million in damages awarded by the jury for infringement through June 2023, plus $19.5 million in supplemental damages, $119.4 million in accrued royalties and $22.9 million in interest.

Going forward, Guardant is required under the judgment to pay a 6% royalty on covered sales through March 2033, when the patents expire.

The technology at the center of the case traces back to research at the University of Washington, where scientists, including co-founder Jesse Salk, developed Duplex Sequencing as a way to make DNA sequencing more accurate. Salk — who stepped down as CEO of TwinStrand in 2022 — now is the co-founder of cancer diagnostics startup CytoTerra.

The molecular biologist and clinical oncologist is the grandson of the late Jonas Salk, the scientist who discovered and developed the polio vaccine.

TwinStrand says its Duplex Sequencing technology can improve the accuracy of next-generation sequencing by more than 10,000-fold, allowing researchers to detect extremely rare genetic mutations that can be obscured by sequencing errors.

“Duplex Sequencing solved an accuracy problem the sequencing field had worked on for years, and this judgment affirms the jury’s finding that Guardant Health built products on that invention without a license,” said Chad Waite, chair of the TwinStrand board of directors, in a press release. “We remained steadfast in our conviction that the facts would prevail, and they have. We intend to see this through and stand firmly behind the intellectual property at the core of our technology.”

Salk and his colleagues from the University of Washington launched TwinStrand in 2015 to commercialize the technology. Based in Seattle, the startup raised funding from Madrona Venture Group, Soleus Capital, Janus Henderson Investors, Ridgeback Capital, Alexandria Venture Investments. Section 32 led a $50 million series B round in the company in 2021.

A jury found in November 2023 that Guardant willfully infringed the patents through 11 products and services. The products identified in the judgment include Guardant360, Guardant Reveal, Guardant Shield and other cancer-testing products.

The Delaware court subsequently rejected Guardant’s effort to overturn the verdict or obtain a new trial. In June, the court also awarded TwinStrand and UW ongoing royalties and supplemental damages. The final judgment now formalizes those awards.

Guardant is not accepting the ruling.

The California-based precision oncology company said Monday that it plans to appeal the judgment, arguing that the court’s order covers products that existed at the time of the 2023 trial and that many have since been discontinued or substantially upgraded. Guardant also said current versions of its Reveal and Shield products are excluded from the final district court order.

Guardant — founded in 2012 — said the judgment and collection of potential royalties will be stayed pending the appeal.

“We strongly disagree with this decision and will promptly be appealing for its overturn,” said John Saia, Guardant Health Chief Legal Officer, in a press release. “We have full faith in the strengths and merits of Guardant’s intellectual property and R&D and are confident we will ultimately prevail on appeal.”

Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode the human immune system.

But as artificial intelligence exploded across life sciences, he recognized a growing divide: the groups spending immense resources to generate high-quality research data rarely receive fair compensation when AI developers use those assets to build commercial tools.

Now, the veteran biotech founder is stepping out with a new Bellevue startup called Harell Data that just scored $15 million in funding from Fuse, Cercano Management and others.

“The goal of the company is to connect AI modelers to proprietary training sets to enable the solution of challenging scientific problems,” said Robins in an email to GeekWire. “At present, the entities that generate proprietary training data using their own technology and expense do not have a good way to commercialize the data. So they effectively sit on it.”

High-profile successes like AlphaFold thrived because they drew on decades of publicly available, experimentally derived protein structures, Robins said.

But in many critical areas of biology and medicine, generating high-quality datasets requires millions of dollars and years of labor. The entities that own this data currently have no secure, profitable way to share it, so it remains sitting in isolated silos.

Harell Data Corp. is built to serve as a secure bridge between data creators and world-class AI modelers. It works like this:

• Secure Cloud Platform: Data creators host their proprietary datasets on Harell’s platform, allowing machine learning groups to train models without the raw underlying data ever leaving the secure environment.
• Direct Revenue Sharing: Instead of waiting years for speculative downstream drug royalties, data owners earn a direct share of the compute revenue generated during training runs.
• Compound Value: As models improve through training on these rich datasets, the intrinsic value of the underlying data becomes more valuable.

While the startup is initially targeting problems Robins knows best — largely around computational medicine — he emphasizes that the data-silo problem spans across scientific disciplines, from materials science to imaging.

“If the business works right, we should be able to enable solutions to really important problems,” he said.

The company’s name also carries a fun personal story. When Robins decided to start the venture, he asked his 8-year-old son, Ellis, for a recommendation. Within seconds, his son suggested “Harell”: a combination of “Harlan” and “Ellis.”

“No offense to the large cap cloud compute companies, but it sounds better to me than any of their names, and things seem to have worked out OK for them so I went with it,” said Robins.

Robins, who continues to serve as a consultant focusing on scientific strategy at Adaptive Biotechnologies, has built an 11-person team split between Bellevue and Palo Alto, California. The team includes Chief Technology Officer Rakesh Nair, Head of Operations Saray Covey, and Head of Sales Analise Polsky.

Early access for the platform is launching this week with initial datasets provided by partners including Seattle-based A-Alpha Bio and Adaptive Biotechnologies.

Adaptive, which is publicly-traded with a market value of $3.9 billion, earlier this year spun out a new startup called Digital Biotechnologies that is developing DNA sequencing technology. 

The biotech publication Timmerman Report first reported on the news of Harell Data.

InduPro, a 4-year-old biotech startup with operations in Seattle and Cambridge, Mass., this week announced $77 million in series B funding as it begins a Phase 1 clinical trial of its lead cancer drug candidate.

The company said that the first patient has been dosed in the trial of IDP-001, an experimental antibody-drug conjugate designed to target cancer cells through a combination of two proteins on their surface.

The early-stage trial is enrolling adults with advanced or metastatic non-small cell lung cancer and other solid tumors whose disease has progressed following standard treatment. Researchers will evaluate the drug’s safety, tolerability, drug behavior and early signs of antitumor activity.

InduPro is developing drugs based on the spatial relationships between proteins on the surface of cells. The company says its approach can identify combinations of targets that are close together on cancer cells but not on normal tissue, potentially allowing drugs to more selectively attack tumors.

The Series B was led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi and Eli Lilly and Company.

“We are delighted to have the support of this outstanding group of life sciences investors and strategic partners who recognize the potential of our proximity-guided platform to create precision therapeutics in oncology and autoimmune disease,” said InduPro CEO Prakash Raman in a press release.

Raman is a longtime biopharma executive who previously served as president and CEO of Ribon Therapeutics. Before that, he spent nearly 14 years at Novartis, where he served as vice president and global head of business development and licensing for the Novartis Institutes for Biomedical Research.

The company’s president and chief scientific officer is Scott Lesley, who previously served as vice president of discovery biologics at Merck.

InduPro said the new funding will support the Phase 1 development of IDP-001 and further development of its preclinical pipeline, which includes programs targeting cancer and autoimmune diseases.

Earlier this year, InduPro inked a strategic collaboration and licensing agreement with Eli Lilly covering up to three oncology targets, a deal worth up to approximately $950 million.

Listen to the session or watch below

Billions of dollars are flooding into efforts to reverse aging as scientists explore ways to return cells to a younger state. But how far off are these experimental treatments? Will they really work? Watch a conversation exploring longevity’s new focus.

Speakers: Mary Beth Griggs, science editor and Jessica Hamzelou, senior biotechnology reporter

Recorded on June 30, 2026

Related Stories:

• Why “reprogramming” is the buzziest approach to reversing aging right now
• How scientists want to make you young again
• Sam Altman invested $180 million into a company trying to delay death